The court had in May set up a five-member National Rare Diseases' Committee (NRDC) to implement the Centre's rare diseases policy to ensure that its benefits reach patients. The panel held discussions with companies involved in research, manufacture and sale of therapies of rare diseases, including Sanofi, Sarepta and Roche, on July 17, the government informed the court earlier this month.
